{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:11:26Z","timestamp":1787886686078,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001027","name":"Department of Health and Ageing, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01DA040506-01"],"award-info":[{"award-number":["1R01DA040506-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.drugpo.2018.08.013","type":"journal-article","created":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T22:50:52Z","timestamp":1540162252000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-3473","authenticated-orcid":false,"given":"Evan B.","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Powis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2028","authenticated-orcid":false,"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Christine","family":"Thurnheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya L.","family":"Applegate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Quiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Siriragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-2017","authenticated-orcid":false,"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2018.08.013_bib0005","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis c virus infection in the united states","volume":"163","author":"Barua","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.drugalcdep.2017.04.003","article-title":"Belgian experience with direct acting antivirals in people who inject drugs","volume":"177","author":"Bielen","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0020","first-page":"17","article-title":"Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2\/3 infection: The ACTIVATE study","author":"Cunningham","year":"2017","journal-title":"Bmc Infectious Diseases"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0025","article-title":"A global profile of people who inject drugs: Systematic reviews of characteristics, prevalence of injecting and of HIV, hepatitis B and hepatitis C","author":"Degenhardt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist TherapyA randomized TrialElbasvir\u2013Grazoprevir in persons with HCV receiving OAT","volume":"165","author":"Dore","year":"2016","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0040","first-page":"227a","article-title":"C-EDGE CO-STAR: Efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy","volume":"62","author":"Dore","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178398","article-title":"Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response","volume":"12","author":"Elsherif","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jhep.2010.10.033","article-title":"Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users","volume":"55","author":"Grebely","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2017.05.020","article-title":"Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2\/3 infection: The ACTIVATE study","author":"Grebely","year":"2017","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0060","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in people with chronic hepatitis C viris infection and recent injecting drug use: The SIMPLIFY study","author":"Grebely","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0065","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0070","first-page":"S776","article-title":"On-treatment illicit drug use did not impact treatment outcome during therapy with ledipasvir-sofosbuvir with or without ribavirin in the phase 3 ion-1 study","volume":"64","author":"Grebely","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","author":"Grebely","year":"2017","journal-title":"Nature Review Gastroenterology Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0080","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/cid\/ciw580","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: The role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Research"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0100","article-title":"High rates of sustained virological response in people who inject drugs treated with all-oral direct acting antiviral regimens","author":"Litwin","year":"2016","journal-title":"5th International Symposium on Hepatitis Care in Substance Users"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0105","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1478-3231.2010.02341.x","article-title":"Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C","volume":"30","author":"Manolakopoulos","year":"2010","journal-title":"Liver International"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0110","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1478-3231.2011.02461.x","article-title":"Adherence to treatment and quality of life during hepatitis C therapy: A prospective, real\u2010life, observational study","volume":"31","author":"Marcellin","year":"2011","journal-title":"Liver International"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0115","first-page":"125","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","volume":"3","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11904-017-0358-8","article-title":"HCV cure and reinfection among people with HIV\/HCV coinfection and people who inject drugs","volume":"14","author":"Martinello","year":"2017","journal-title":"Current HIV\/AIDS Reports"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0125","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/hep.28844","article-title":"Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study","volume":"64","author":"Martinello","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","author":"Mason","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2334-14-203","article-title":"Factors influencing adherence in hepatitis-C infected patients: A systematic review","volume":"14","author":"Mathes","year":"2014","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0140","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ajg.2017.87","article-title":"Medicaid reimbursement for Oral direct antiviral agents for the treatment of chronic hepatitis C","volume":"112","author":"Ooka","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0145","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s10461-011-9942-x","article-title":"Adherence to highly active antiretroviral therapy (HAART): A meta-analysis","volume":"15","author":"Ortego","year":"2011","journal-title":"AIDS Behav"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1590\/S0004-28032010000300005","article-title":"Should active injecting drug users receive treatment for chronic hepatitis C?","volume":"47","author":"Papadopoulos","year":"2010","journal-title":"Arquivos de Gastroenterologia"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0155","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","article-title":"High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study","volume":"10","author":"Petersen","year":"2016","journal-title":"Hepatology International"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0160","first-page":"1135A","article-title":"ABT-450\/r\/ombitasvir+ dasabuvir with or without ribavirin in HCV genotype 1\u2013Infected patients receiving stable opioid substitution treatment: Pooled analysis of efficacy and safety in phase 2 and phase 3 trials","volume":"60","author":"Puoti","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/aid.2006.22.393","article-title":"Poor response to hepatitis C virus (HCV) therapy in HIV-and HCV-coinfected patients is not due to lower adherence to treatment","volume":"22","author":"Sol\u00e0","year":"2006","journal-title":"AIDS Research & Human Retroviruses"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0170","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/MEG.0b013e3281bcb8d8","article-title":"Adherence to hepatitis C treatment in recovering heroin users maintained on methadone","volume":"19","author":"Sylvestre","year":"2007","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0175","series-title":"Global hepatitis report 2017","author":"WHO","year":"2017"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.2008.03834.x","article-title":"Community\u2010based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use","volume":"29","author":"Wilkinson","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.drugpo.2018.08.013_bib0185","series-title":"Combating hepatitis B and C to reach elimination by 2030","author":"World Health Organization","year":"2016"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395918302457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395918302457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:42:54Z","timestamp":1760629374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395918302457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":37,"alternative-id":["S0955395918302457"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.013","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}